Comparative Pharmacology
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAZIDIME SODIUM IN PLASTIC CONTAINER versus CEPHALOTHIN SODIUM.
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER vs CEPHALOTHIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis and death.
Cephalothin is a first-generation cephalosporin with bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs).
1-2 g IV every 8 hours for pseudomonal infections; 500 mg to 1 g IV every 8-12 hours for uncomplicated UTIs.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
1.5–2.0 hours in normal renal function; prolonged to 15–30 hours in ESRD.
Terminal elimination half-life: 0.5-1.0 hour in adults with normal renal function. In anuria, prolonged to 2.5-8 hours. Dose adjustment required for CrCl <50 mL/min.
Primarily renal (80–90% unchanged via glomerular filtration); biliary/fecal <1%.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion). Minor biliary excretion (1-5%). Fecal elimination negligible.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic